Moleculin Biotech (MBRX) Registration filing summary

Company overview and business model

• Late-stage pharmaceutical development focused on Annamycin, a next-generation anthracycline for relapsed/refractory acute myeloid leukemia (AML), currently in pivotal Phase 2/3 MIRACLE trial.

• Additional portfolios target hard-to-treat cancers and viruses, with clinical and preclinical research collaborations, primarily based on discoveries from MD Anderson Cancer Center.

• Three core technologies, each with at least one drug candidate having completed Phase 1 or higher clinical trials.

Financial performance and metrics

• As of March 31, 2026, net tangible book value was $4.0 million, or $0.76 per share.

• After the offering, net tangible book value per share would rise to $1.32, with immediate dilution of $0.87 per share for new investors at the assumed offering price.

• 5,336,350 shares outstanding before the offering; 9,902,560 shares expected after, assuming full exercise of pre-funded warrants and no exercise of common warrants.

Use of proceeds and capital allocation

• Estimated net proceeds of $9.1 million, assuming full sale at $2.19 per share, after fees and expenses.

• Proceeds intended to advance Annamycin through clinical development and for working capital.

• Management has broad discretion in application of proceeds; funds not immediately used will be invested in short-term instruments.